New hope for leukemia patients out of options
NCT ID NCT06549790
Summary
This early-stage study is testing a new oral drug called NMS-03597812 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can help put the cancer into remission. The study will include a specific group of patients whose cancer has a TP53 gene mutation, which often makes it harder to treat.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood and Marrow Transplant Group of Georgia
RECRUITINGAtlanta, Georgia, 30342, United States
-
City of Hope - Duarte
RECRUITINGDuarte, California, 91010, United States
-
Gabrail Cancer Research Center
RECRUITINGCanton, Ohio, 44718, United States
-
Mayo Clinic Cancer Center (MCCC) - Rochester
WITHDRAWNRochester, Minnesota, 55905, United States
-
Medical Oncology Hematology Consultants
RECRUITINGNewark, Delaware, 19713, United States
-
Rocky Mountain Cancer Centers
RECRUITINGAurora, Colorado, 80012, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.